Senior Director
Current
Oct 2024 - Present
AeroLeads people directory · profile
Jonathan Sims Email & Phone Number
Senior Director at Eli Lilly and Company
at
Eli Lilly and Company
2 phones found
area 859
LinkedIn matched
✓ Verified August 2026
4 data sources
Profile completeness 100%
Current company
Role
Senior Director at Eli Lilly and Company
Location
Indianapolis, Indiana, United States
Who is Jonathan Sims? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Jonathan Sims is listed as Senior Director at Eli Lilly and Company at Eli Lilly and Company, based in Indianapolis, Indiana, United States. AeroLeads shows phone signal with area code 859 and a matched LinkedIn profile for Jonathan Sims.
Jonathan Sims previously worked as Senior Director at Eli Lilly And Company and Director at Eli Lilly And Company. Jonathan Sims holds Ph.D., Molecular & Biomedical Pharmacology from University Of Kentucky College Of Medicine.
Company email context
Email format at Eli Lilly and Company
This section adds company-level context without repeating Jonathan Sims's masked contact details.
Eli Lilly and Company
Review company-level records connected to Jonathan Sims before choosing the right outreach path.
Profile bio
About Jonathan Sims
Jonathan Sims is a Senior Director at Eli Lilly and Company at Eli Lilly and Company. He possess expertise in cell culture, cell, pcr, flow cytometry, immunology and 22 more skills. Colleagues describe him as "Jonathan joined my lab as an undergraduate researcher in August, 2003. I was very pleased with his maturity and his performance during his time at Western Kentucky University. Jonathan was polite, and he had a good attitude. During his time in my lab, I observed Jonathan’s strong work ethic. He was reliable and he worked well independently. These qualities are cherished by faculty who sponsor undergraduate workers. My lab studies bacterial viruses and Jonathan assisted in the characterization of Salmonella specific bacteriophages from swine manure lagoons. Jonathan was always willing to learn new techniques and to optimize protocols. His project involved the isolation of phage plaques, the growth of high titer stocks, the purification of the phage particles by cesium chloride centrifugation and the preparation of samples for electron microscopy (EM). Jonathan’s EM pictures were very good. They were presented at scientific conferences and published in the Journal of Environmental Quality (2006). Jonathan was one of the most hard working and dependable undergraduates who have worked my lab."
Listed skills include Cell Culture, Cell, Pcr, Flow Cytometry, and 23 others.
Current workplace
Jonathan Sims's current company
Company context helps verify the profile and gives searchers a useful next step.
11 roles
Jonathan Sims work experience
A career timeline built from the work history available for this profile.
Director
1. Laquer V, Parra V, Lacour JP, Takahashi H, Knorr J, Okragly AJ, James DE, Sims JT, Chang CY, Chao J, Klekotka P. (2022) IL-33 antibody failed to demonstrate benefit in a phase 2 double-blind, randomised placebo-controlled study in adult patients with moderate-to-severe atopic dermatitis. Br J Dermatol. 2022 Apr 28. https://doi.org/10.1111/bjd.216312. Dörner T, Tanaka Y, Dow ER, Koch AE, Silk M, Ross Terres JA, Sims JT, Sun Z, de la Torre I, Petri M. (2022) Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus. Ann Rheum Dis. 2022 May 24:annrheumdis-2022-222335. https://doi.org/10.1136/annrheumdis-2022-2223353. Sims JT, Chang CY, Poorbaugh J, Daniels M, Beasley SL, Zhang L, Rodgers GH, Lena F, Lacerenza LG, Sposato B, Dupont A, Susen S, Casalini G, Corbellino M, Stebbing J, Krishnan V. (2022) Longitudinal assessment of systemic steroid therapy on hyperinflammatory endothelial biomarker profiles and serology responses of COVID-19 patients. J Transl Med. 2022 Sep 8;20(1):411. https://doi.org/10.1186/s12967-022-03583-54. Parthasarathy V, Cravero K, Deng J, Sun Z, Engle SM, Auxier AN, Hahn N, Sims JT, Okragly AJ, Alphonse MP, Kwatra SG. (2022) Circulating plasma IL-13 and periostin are dysregulated type 2 inflammatory biomarkers in prurigo nodularis: A cluster analysis. Front Med (Lausanne). 2022 Dec 6;9:1011142. https://doi.org/10.3389/fmed.2022.10111425. Ju T, Labib A, Nattkemper L, Engle S, Auxier A, Hahn N, Sissons S, Sims JT, Sun Z, Okragly AJ, Yosipovitch G. (2023) Serum Interleukin-13 and Caspase 8 are Elevated in Prurigo Nodularis. Acta Derm Venereol. 2023 Feb 7;103:adv00861. https://doi.org/10.2340/actadv.v103.4804
Mar 2022 - Oct 2024
Principal Research Scientist
1. Zhou, J., Gemperline, D.C., Turner, M.J., Oldach, J., Molignano, J., Sims, J.T., Stayrook, K.R. (2021) Transcriptomic Analysis of Healthy and Atopic Dermatitis Samples Reveals the Role of IL-37 in Human Skin. ImmunoHorizons. 2021 Oct 26;5(10):830-843. https://doi.org/10.4049/immunohorizons.21000552. Engle, S.M., Chang, C.Y., Ulrich, B.J., Satterwhite, A., Hayes, T., Robling, K., Sissons, S.E., Schmitz, J., Tepper, R.S., Kaplan, M.H., Sims, J.T. (2021) Predictive biomarker modeling of pediatric atopic dermatitis severity based on longitudinal serum collections. Clinical & Experimental Immunology. Nov 30, 2021; uxab009, https://doi.org/10.1093/cei/uxab009.3. Sims JT, Poorbaugh J, Chang CY, Holzer TR, Zhang L, Engle SM, Beasley S, Doman TN, Naughton L, Higgs RE, Kallewaard N, Benschop RJ. (2022) Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab. J Transl Med. 2022 Mar 18;20(1):134. https://doi.org/10.1186/s12967-022-03345-3
Oct 2021 - Mar 2022
Senior Research Scientist
1. Sims, JT, Krishnan, V, Chang, CY, Engle, SM, Casalini, G, Rodgers, GH, Nickoloff, BJ, Konrad, RJ, de Bono, S, Higgs, RE, Benschop, RJ, Ottaviani, S, Cardoso, A, Nirula, A, Corbellino, M, Stebbing, J (2020) Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19. J Allergy Clin Immunol. Sep 10 https://doi.org/10.1016/j.jaci.2020.08.0312. Sims, J.T., Chang, C.Y., Higgs, R.E., Liu, Y., Engle, S.M., Sissons, S.E., Rodgers, G.H., Simpson, E.L., Silverberg, J.I., Forman, S.B., Janes J.M., Colvin, S.C., Guttman-Yassky, E. (2021) Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe disease. Experimental Dermatology. 18 May https://doi.org/10.1111/exd.14389
Oct 2019 - Sep 2021
Research Scientist
Dec 2013 - Sep 2019
Post Doctoral Scientist
Joint research position with the Biological Mass Spectrometry and Autoimmunity groups in the Tailored Therapeutics division of LRL. My work focused on the phosphoproteomic analysis of cytokine signaling pathways.
Aug 2012 - Nov 2013
Graduate Student In Molecular & Biomedical Pharmacology Department
I studied the role of the Abelson family (c-Abl, Arg) non-receptor tyrosine kinases in breast cancer and melanoma progression in order to devise new therapeutic strategies for the treatment of highly metastatic forms of disease. ------1. Srinivasan, D., Sims, J.T., Plattner R. (2008) Deregulated Abl Kinases Promote Proliferation, Anchorage-Independent Growth and Survival of Aggressive Breast Cancer Cells. Oncogene, 14;27(8):1095-105. 2. Sims, J.T., and R. Plattner. (2009) MTT assays cannot be utilized to study the effects of STI571/Gleevec on the viability of solid tumor cell lines. Cancer Chemotherapy and Pharmacology, Aug;64(3):629-33. 3. Sims, J.T., Ganguly, S., Fiore, L, Holler, C., Park, E.S., Plattner, R. (2009) STI571 (Gleevec) sensitizes breast cancer cells to 5-Fluorouracil, Cisplatin, and Camptothecin in a cell type-specific manner. Biochemical Pharmacology, Aug 1;78(3):249-60.4. Zhao, H., Ou-Yang, F., Chen I., Hou, M., Yuan, S.F., Chang, H., Lee, Y., Plattner R., Waltz, S., Ho, S., Sims, J., Wang, S. (2010) Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer. Neoplasia, Mar;12(3):214-23.5. Ganguly, S., Fiore L.S., Sims, J.T., Friend, J.W., Srinivasan, D., Cibull, M.L., Wang, C., Novak, M., Kaetzel, D.M., Plattner, R. (2011) c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression. Oncogene, Sep 5.6. Sims JT, Ganguly SS, Bennett H, Friend JW, Tepe J, Plattner R. (2013) Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1. PLoS One. 2013;8(1):e55509.
Aug 2006 - Apr 2012
Research Assistant In Microbiology, Immunology, & Molecular Genetics Department
Studied the binding properties of Anaplasma phagocytophilum that promote infection of human neutrophils using a variety of molecular and microbiological techniques, cell culture, flow cytometry, and IFA. ------1. Reneer, D.V., Kearns, S.A., Yago, T., Sims, J., Cummings, R.D., McEver, R.P., Carlyon, J.A. (2006) Characterization of a sialic acid- and P-selectin glycoprotein ligand-1-independent adhesin activity in the granulocytotropic bacterium Anaplasma phagocytophilum. Cellular Microbiology, Dec;8(12):1972-842. Huang, B., Troese, M.J., Ye, S., Sims, J.T., Galloway, N.L., Borjesson, D., Carlyon, J.A. (2010) Anaplasma phagocytophilum APH1387 is expressed throughout bacterial intracellular development and localizes to the pathogen-occupied vacuolar membrane. Infect Immun, May;78(5):1864-73.3. Huang, B., Troese, M.J., Howe, D., Ye, S., Sims, J.T., Heinzen,R., Borjesson, D., Carlyon, J.A. (2010) Anaplasma phagocytophilum APH_0032 is expressed late during infection and localizes to the pathogen-occupied vacuolar membrane. Microb Pathog, Nov;49(5):273-84.
Jan 2005 - Aug 2005
Undergraduate Research Assistant In Biology Department
Purified and concentrated Salmonella-specific bacteriophage cultures and identified novel strains using Electron Microscopy (TEM). ------1. M. R. McLaughlin, M. F. Balaa, J. Sims and R. King. (2006) "Isolation of salmonella bacteriophages from swine effluent lagoons." J Environ Qual 35(2): 522-8. https://doi.org/10.2134/jeq2005.0080
Aug 2003 - Dec 2004
Undergraduate Research Assistant In Chemistry Department
Analyzed novel compounds synthesized through directed ortho-metalation of Dimethylarylamines using column chromatography and Gas Chromatography/Mass Spectrometry.
Jan 2003 - May 2004
Summer Research Assistant
Extensively used cloning, sequencing, and PCR techniques to identify viral DNA & RNA via novel isolation/detection methods. ------1. Amy L Clem, Jonathan Sims, Sucheta Telang, John W Eaton and Jason Chesney. (2007) "Virus detection and identification using random multiplex (RT)-PCR with 3'-locked random primers." Virol J. Jun 28;4:65. https://doi.org/10.1186/1743-422X-4-65
May 2003 - Aug 2003
4 education records
Jonathan Sims education
Ph.D., Molecular & Biomedical Pharmacology
University Of Kentucky College Of Medicine
Certificate In Business Administration
University Of Kentucky
B.S., Recombinant Genetics, Chemistry
Western Kentucky University
A.A., General
Florida College
FAQ
Frequently asked questions about Jonathan Sims
Quick answers generated from the profile data available on this page.
What company does Jonathan Sims work for?
Jonathan Sims works for Eli Lilly and Company.
What is Jonathan Sims's role at Eli Lilly and Company?
Jonathan Sims is listed as Senior Director at Eli Lilly and Company at Eli Lilly and Company.
What is Jonathan Sims's phone number?
AeroLeads has found 2 phone signal(s) with area code 859 for Jonathan Sims at Eli Lilly and Company.
Where is Jonathan Sims based?
Jonathan Sims is based in Indianapolis, Indiana, United States while working with Eli Lilly and Company.
What companies has Jonathan Sims worked for?
Jonathan Sims has worked for Eli Lilly And Company, University Of Kentucky, Western Kentucky University, and University Of Louisville.
How can I contact Jonathan Sims?
You can use AeroLeads to view verified contact signals for Jonathan Sims at Eli Lilly and Company, including work email, phone, and LinkedIn data when available.
What schools did Jonathan Sims attend?
Jonathan Sims holds Ph.D., Molecular & Biomedical Pharmacology from University Of Kentucky College Of Medicine.
What skills is Jonathan Sims known for?
Jonathan Sims is listed with skills including Cell Culture, Cell, Pcr, Flow Cytometry, Immunology, Assay Development, Dna, and Biology.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial